Key Highlights

  • SPTX reported a third-quarter 2026 net loss of $26.4 million, or $0.49 per share, versus $22.5 million, or $9.43, a year earlier.
  • Cash, cash equivalents and investments were $403.8 million on Sep 30, 2026, expected to fund operations into 2029.
  • Research and development expenses rose to $23.9 million from $20.5 million, led by $10.2 million spent on GlyphAllo.
  • The nine-month net loss reached $114.4 million, compared with $50.7 million, as general and administrative expenses rose to $53.8 million.
  • The company sold 14,446,658 shares in its IPO at $18.00, raising net proceeds of about $238.4 million.

Third-Quarter Net Loss Widens to $26.4 Million as Trial Spending Climbs

Seaport Therapeutics (NASDAQ:SPTX) reported results for the third quarter ended Sep 30, 2026 in a quarterly filing dated Nov 2, 2026. The company, which has no product revenue, posted a net loss of $26.4 million versus $22.5 million in the prior-year quarter. Loss per share was $0.49, compared with $9.43, reflecting a far larger share count after its initial public offering (IPO).

Operating expenses rose to $30.3 million from $25.4 million. Other income, net, increased to $4.1 million from $3.0 million, mainly on interest earned on IPO proceeds.

GlyphAllo Costs Drive R&D Higher While Public Company Expenses Lift G&A

Seaport is a clinical-stage company developing oral medicines for depression, anxiety and other neuropsychiatric disorders using its Glyph platform. Research and Development expenses were $23.9 million, up $3.4 million from $20.5 million. GlyphAllo program costs grew to $10.2 million from $7.7 million as the Phase 2b BUOY-1 trial progressed, while GlyphAgo costs fell to $3.4 million from $4.2 million.

General and administrative expenses increased to $6.5 million from $5.0 million, on higher compensation, professional fees and insurance costs tied to operating as a public company.

For the nine months, the net loss was $114.4 million versus $50.7 million, or $3.72 per share. General and administrative expenses jumped to $53.8 million from $15.7 million, largely because of $35.7 million of added non-cash Stock Compensation linked to awards vested or accelerated at the IPO. Research and development expenses rose to $69.9 million from $44.4 million.

IPO Proceeds Fund Pipeline Milestones From BUOY-1 Data to a GlyphAgo Phase 2a Trial

The company completed its IPO in the second quarter of 2026, selling 14,446,658 shares at $18.00 each for net proceeds of about $238.4 million. Its accumulated Deficit was $228.5 million at quarter end, and net cash used in Operating Activities was $69.0 million for the nine months, versus $51.3 million.

GlyphAllo, a prodrug of allopregnanolone, is being tested in the Phase 2b BUOY-1 trial in major depressive disorder, with topline data expected in the first half of 2027. In September 2026 the company reported positive Phase 1 driving simulation results showing that evening dosing did not impair next-morning driving versus placebo.

For GlyphAgo, a prodrug of agomelatine, the first patient was dosed in a Phase 2a trial in October 2026, with topline data expected in early 2028. A Phase 2/3 trial in generalized anxiety disorder is planned to start in the first half of 2027. First-in-human-enabling studies for Glyph2BLSD are expected by year-end 2027.

Funding Into 2029 Sets the Timeline for the 2027 BUOY-1 Readout

Management said its $403.8 million of cash, equivalents and investments should cover operating expenses and Capital needs into 2029, though it expects losses and spending to keep rising. The next dated catalyst in the filing is the BUOY-1 topline readout in the first half of 2027.